Perrigo Q3 2026 Financial Results - PERRIGO CO PLC

Explicit Guidance:

• FY2026 Core Net Sales: Expect decline of 2.5% to 3.6% (reported) and 2.7% to 3.8% (organic).
• FY2026 Core Adjusted Operating Margin: Expected range of 14.0% to 15.0%.
• FY2026 Core Adjusted EPS: Expected range of $2.15 to $2.35.
• FY2026 All-in Adjusted Gross Margin: Expected range of 37.8% to 38.8% (reflecting exclusion of infant formula).
• FY2026 All-in Adjusted Operating Margin: Expected range of 14.3% to 15.3%.
• FY2026 All-in Adjusted EPS: Expected range of $2.25 to $2.45.
• FY2026 All-in Net Sales: Expected decline of 4.6% to 5.7% (excluding infant formula).
• FY2026 Key Assumptions: Net interest expense of ~$162 million; Adjusted effective tax rate of ~14%; Diluted shares outstanding of ~140 million; Year-end net leverage of ~4.0x; Cash from operations to adjusted net income ratio in the low-to-mid 60% range.

Business-Segment Outlook:

• Infant Formula: Divestment agreement finalized; reported as discontinued operations starting Q4 2026, removing associated losses and capex needs.
• Oral Care: Under strategic review for potential divestiture alongside infant formula; process ongoing.
• Dermacosmetics: Successfully divested; impacts 2027 results via margin normalization.
• Self-Care (Core): Margins expected to improve in FY2027 due to resolved under-absorption in OTC categories and operational enhancement savings.
• Specialty Care: Continued investment in skin health (Compete, Jungle Formula) and Women's health (LL1, Appeal) expected to drive share gains.
• Share Performance: Projected to continue gaining share in U.S. store brand OTC and key European brands; e-commerce share already exceeds total market share (22% vs. 13% in 2022) and expected to benefit disproportionately as channel growth accelerates.
• Operational Savings: Operational Enhancement Program on track to deliver $60M–$80M in cost savings in FY2026; $42M realized year-to-date.

Market and Competitive Outlook:

• Retailer Inventory: Cautious inventory positioning observed heading into Q4 cough/cold season; retailers have not restocked to previous levels, creating headwinds despite early signs of illness recovery.
• Seasonality: Cough/cold season trends shifting later due to climate factors; potential restocking tailwinds may materialize in Q4 or early FY2027.
• European Demand: Consumer environment remains soft with declines tracking below prior expectations; however, rate of decline is improving sequentially.
• U.S. Demand: Category volumes returned to modest growth in Q3; consumption trends strengthening.
• Pricing/Inflation: Inflationary pressures anticipated to persist into FY2027; no specific pricing guidance given.
• GLP-1 Adjacency: Launching digestive health portfolio activation to capture consumers on GLP-1 journeys, expected to shift mix toward faster-growing sub-categories.

Macro / Industry Outlook:

• Consumer Environment: Management notes a challenging but stabilizing environment; confidence in underlying business trajectory despite external headwinds.
• Currency: FX translation was a headwind in Q3; no explicit FX guidance provided for full year other than impact on reported numbers.
• Tariffs: One-time benefit of ~$4.5M recorded in Q3 due to tariff recovery; this benefit is expected to reverse in FY2027.
• Tax Rate: Q3 effective tax rate dropped to 3.5% due to jurisdictional mix; expected to normalize to ~14% in FY2027 following divestitures.

Strategic Initiatives:

• Capital Allocation: Net proceeds from infant formula divestment to be deployed toward sustainable growth, debt reduction, and maintaining disciplined framework; dividend reviewed quarterly.
• CapEx Reduction: Infant formula divestiture and network optimization expected to significantly reduce capital requirements, allowing capital shift to core OTC high-return opportunities.
• Digital Expansion: Doubling down on e-commerce channel, leveraging higher market share in a faster-growing segment.
• Portfolio Simplification: Continuing to exit non-core assets to focus on areas with "greatest right to win"; aim to exit 2026 as a simpler, more focused self-care company.
• Brand Investment: Allocating capital to demand generation, innovation in high-value categories, and retailer co-innovation.

Risks and Headwinds to Outlook:

• Inventory Reversal: Risk that retailer inventory rebuilding may not occur in Q4 or may be delayed into FY2027, limiting sales recovery.
• Seasonal Variability: Uncertainty regarding the intensity and timing of the cough/cold season and consumer incidence rates.
• Europe Softness: Continued underperformance in European consumer environment could further impact full-year results.
• Tax and Tariff Normalization: Loss of one-time tax benefits and tariff recoveries in FY2027 may pressure margins compared to current year.
• Inflation: Persistent inflationary pressures expected in 2027 affecting costs.
• Execution Risk: Complexity reduction and integration of new portfolio require precise execution to translate progress into consistent results.

Management Tone on the Future:

• Confidence Level: High confidence in the long-term trajectory and asset quality ("hard to replicate" position); acknowledges current complexity as the primary constraint.
• Sentiment: Cautiously optimistic; emphasizes "sequential improvement" in operating performance and market share gains as proof of the 3S plan's efficacy.
• Strategic Shift: Decisive move away from "complexity" toward "simplification"; focus on disciplined capital allocation and high-return investments.
• Guidance Consistency: Updated outlook reflects a more "measured" and "prudent" view compared to prior expectations, citing retailer caution and European weakness, while maintaining faith in the underlying business.

Miscellaneous:

• Discontinued Operations: Infant formula results will be excluded from all core and all-in reporting starting Q4 2026.
• Divestiture Proceeds: Infant formula divestment expected to remove cash consumption associated with the segment.
• E-commerce Metrics: U.S. e-commerce category volume up nearly 15% YTD; Parago's e-commerce share represents 22% of U.S. volume.